Amendments to the Claims:

Claims 1-35 (Canceled)

- 36. (Currently amended) A transgenic mouse whose genome comprises a <u>null homozygous</u> disruption in the endogenous mouse glucocorticoid-induced receptor <u>allelegene</u>, wherein the transgenic mouse lacks production of functional glucocorticoid-induced receptor and exhibits, relative to a wild-type control mouse, hyperactivity, reduced anxiety, decreased propensity toward behavioral despair, or decreased propensity toward depression.
- 37. (Currently amended) The transgenic mouse of claim 36, wherein the <u>mouse exhibits</u> hyperactivity <u>comprisingeomprises</u> an increase in total distance traveled in an open field environment, relative to a wild-type <u>control</u> mouse.
- 38. (Currently amended) The transgenic mouse of claim 36, wherein the <u>mouse exhibits</u> reduced anxiety <u>comprises comprising</u> an increase in percent time spent in a central region of an open field environment, relative to a wild-type <u>control</u> mouse.
- 39. (Currently amended) The transgenic mouse of claim 36, wherein the <u>mouse exhibits</u> decreased propensity toward behavioral despair <u>comprises comprsing</u> a decrease in time spent immobile while tail suspended, relative to a wild-type <u>control</u> mouse.
- 40. (Currently amended) The transgenic mouse of claim 36, wherein the <u>mouse exhibits</u> decreased propensity toward depression <u>comprises comprising</u> a decrease in time spent immobile while tail suspended, relative to a wild-type <u>control</u> mouse.
- 41. (Currently amended) A cell or tissue obtained isolated from the transgenic mouse of claim 36.

Claims 42-46 (Canceled)

- 47. (Currently amended) A method of producing a the transgenic mouse of claim 36whose genome comprises a homozygous disruption in the endogenous mouse glucocorticoid induced receptor gene, the method comprising:
 - (a) providing a mouse embryonic stem cell comprising a disruption in the endogenous mouse glucocorticoid-induced receptor gene; and
 - (b) introducing the mouse embryonic stem cell into a blastocyst;

- (c) <u>introducing the blastocyst into a pseudopregnant mouse</u>, wherein the pseudopregnant mouse gives birth to chimeric mice; and
- (d) breeding the chimeric mice to produce the transgenic mouse; wherein the transgenic mouse whose genome comprises the homozygous disruption in the endogenous mouse glucocorticoid induced receptor gene lacks production of functional glucocorticoid induced receptor and exhibits hyperactivity, reduced anxiety, decreased propensity toward behavioral despair, or decreased propensity toward depression.
- 48. (Canceled)
- 49. (New) The transgenic mouse of claim 36 wherein said mouse is heterozygous for said null allele.
- 50. (New) The transgenic mouse of claim 36 wherein said mouse is homozygous for said null allele.
- 51. (New) The transgenic mouse of claim 36 wherein said null allele comprises a gene encoding a selectable marker.
- 52. (New) The transgenic mouse of claim 51 wherein said gene is a neomycin resistant gene.
- 53. (New) The transgenic mouse of claim 47 wherein said null allele further comprises a *lacZ* gene.